New drug cocktail aims to wipe out Triple-Positive breast tumors before surgery
NCT ID NCT07299890
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a combination of four drugs (trastuzumab, pertuzumab, palbociclib, and exemestane) given before surgery to 90 people with early-stage triple-positive breast cancer. The goal is to see if this treatment can completely eliminate cancer cells in the breast and lymph nodes. Participants will receive the drugs for a set period before surgery, and researchers will monitor how well the tumors respond and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••